The role of renin-angiotensin-aldosterone system inhibition in chronic kidney disease. (Q30340930)

20 June 2017

1 reference

title

The role of renin-angiotensin-aldosterone system inhibition in chronic kidney disease. (English)

1 reference

20 June 2017

Keith Norris

1

1 reference

20 June 2017

Charles Vaughn

series ordinal

2

1 reference

20 June 2017

publication date

1 May 2003

1 reference

Expert Review of Cardiovascular Therapy

20 June 2017

published in

1 reference

20 June 2017

volume

1

1 reference

20 June 2017

issue

1

1 reference

20 June 2017

page(s)

51-63

1 reference

Nephropathy in patients with type 2 diabetes mellitus

20 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.1.51

Nephrology in China: a great mission and momentous challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.1.51

Identification of persons at high risk for kidney disease via targeted screening: the NKF Kidney Early Evaluation Program

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.1.51

Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.1.51

Renal function: the Cinderella of cardiovascular risk profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.1.51

A comparison of outcomes with angiotensin-converting--enzyme inhibitors and diuretics for hypertension in the elderly.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.1.51

Renal dysfunction complicating the treatment of hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.1.51

Advanced glycation end products: a Nephrologist's perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.1.51

Clinical practice. Nondiabetic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.1.51

Successful blood pressure control in the African American Study of Kidney Disease and Hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.1.51

Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.1.51

Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.1.51

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.1.51

Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.1.51

Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.1.51

Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.1.51

Toleration of high doses of angiotensin-converting enzyme inhibitors in patients with chronic heart failure: results from the ATLAS trial. The Assessment of Treatment with Lisinopril and Survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.1.51

Evolution of drugs that preserve renal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.1.51

TGF-beta 1 as a genetic susceptibility locus for advanced diabetic nephropathy in type 1 diabetes mellitus: an investigation of multiple known DNA sequence variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.1.51

Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.1.51

Peroxisome proliferator-activated receptor-gamma in the renal mesangium

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.1.51

Angiotensin-converting enzyme 2--a new cardiac regulator

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.1.51

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.1.51

Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.1.51

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.1.51

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.1.51

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.1.51

Additive antiproteinuric effect of combined ACE inhibition and angiotensin II receptor blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.1.51

Microalbuminuria in type 1 and type 2 diabetes mellitus: evidence with angiotensin converting enzyme inhibitors and angiotensin II receptor blockers for treating early and preventing clinical nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.1.51

Losartan reduces the costs associated with diabetic end-stage renal disease: the RENAAL study economic evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.1.51

Slowing the progression of chronic renal failure: economic benefits and patients' perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.1.51

Quality of prereferral care in patients with chronic renal insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.1.51

Will angiotensin II receptor antagonists be renoprotective in humans?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.1.51

Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.1.51

Renin-angiotensin system blockade and the risk of hyperkalemia in chronic hemodialysis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.1.51

Aldosterone as a mediator of progressive renal disease: pathogenetic and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.1.1.51

21 January 2018

Identifiers

DOI

10.1586/14779072.1.1.51

1 reference

20 June 2017

1 reference